phgenomicsФармакогенетика и фармакогеномикаPharmacogenetics and Pharmacogenomics2588-05272686-8849LLC "Izdatelstvo OKI"10.24411/2588-0527-2019-10038phgenomics-148Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫCURRENT REVIEWФармакогенетические аспекты эффективности и безопасности терапии тразодономPharmacogenetic aspects of the efficacy and safety of trazodone therapyhttps://orcid.org/0000-0002-1367-1669ДобродееваВ. С.DobrodeevaV. S.

Добродеева Вера Сергеевна – м. н. с. отделения персонализированной психиатрии и неврологии. SPIN-код: 3924-3369

Санкт-Петербург

Dobrodeeva Vera – Junior researcher of the Department of Personalized Psychiatry and Neurology. SPIN-code: 3924-3369

St-Petersburg

dobro.vera@gmail.comhttps://orcid.org/0000-0002-2840-837XШнайдерН. А.ShnayderN. A.

Шнайдер Наталья Алексеевна – д. м. н., профессор, ведущий научный сотрудник отделения персонализированной психиатрии и неврологии. SPIN-код: 6517-0279

Санкт-Петербург

Shnayder Natalia – DM, Professor, Leading Researcher of the Department of Personalized Psychiatry and Neurology. SPIN-code: 6517-0279

St.-Petersburg

https://orcid.org/0000-0003-1874-9434НасыроваР. Ф.NasyrovaR. F.

Насырова Регина Фаритовна – д. м. н., главный научный сотрудник, руководитель отделения персонализированной психиатрии и неврологии. SPIN-код: 3799-0099

Санкт-Петербург

Nasyrova Regina – DM, Senior Researcher, Head of the Department of Personalized Psychiatry and Neurology. SPIN-code: 3799-0099

St.-Petersburg

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» Министерства здравоохранения Российской ФедерацииРоссияV.M. Bekhterev National Medical Research Centre for Psychiatry and NeurologyRussian Federation201923032020012528Copyright © Добродеева В.С., Шнайдер Н.А., Насырова Р.Ф., 20192019Добродеева В.С., Шнайдер Н.А., Насырова Р.Ф.Dobrodeeva V.S., Shnayder N.A., Nasyrova R.F.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/148тразодонфармакогенетикадепрессивное расстройствоОНПперсонализированная медицинаtrazodonepharmacogeneticsmajor depressive disorderSNPpersonalized medicineReferencesBuoli M, Rovera C, Pozzoli SM, et al. Is trazodone more effective than clomipramine in major depressed outpatients? A single-blind study with intravenous and oral administration. CNS Spectrums. 1–7.Buoli M, Rovera C, Pozzoli SM, et al. Is trazodone more effective than clomipramine in major depressed outpatients? A single-blind study with intravenous and oral administration. CNS Spectrums. 1–7.Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk W. Effects of antidepressants on sleep. Curr Ps ychiatry Rep. 2017;19(9):63.Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk W. Effects of antidepressants on sleep. Curr Ps ychiatry Rep. 2017;19(9):63.Smales ET, Edwards BA, Deyoung PN, et al. Trazodone Effects on Obstructive Sleep Apnea and Non-REM Arousal Threshold. Ann Am Thorac Soc. 2015 May;12(5):758–764.Smales ET, Edwards BA, Deyoung PN, et al. Trazodone Effects on Obstructive Sleep Apnea and Non-REM Arousal Threshold. Ann Am Thorac Soc. 2015 May;12(5):758–764.Hamik A, Peroutka SJ. 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol. Psychiatry. 1989;25(5):569–575.Hamik A, Peroutka SJ. 1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol. Psychiatry. 1989;25(5):569–575.Jauch R, Kopitar Z, Prox A, et al. Pharmacokinetics and metabolism of trazodone in man (author’s transl). Arzneimittelforschung (In German). 1976;26:2084–2089.Jauch R, Kopitar Z, Prox A, et al. Pharmacokinetics and metabolism of trazodone in man (author’s transl). Arzneimittelforschung (In German). 1976;26:2084–2089.Mihara K, Otani K, Suzuki A, et al. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Psychopharmacology (Berl.). 1997;133(1):95–98.Mihara K, Otani K, Suzuki A, et al. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Psychopharmacology (Berl.). 1997;133(1):95–98.Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proceedings of the National Academy of Sciences. 1997; 94(8):4028–4033.Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proceedings of the National Academy of Sciences. 1997; 94(8):4028–4033.Saiz-Rodríguez M, Belmonte C, Derqui-Fernández N, et al. Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety. Pharmacogenomics. 2017;18(16):1491–1502.Saiz-Rodríguez M, Belmonte C, Derqui-Fernández N, et al. Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety. Pharmacogenomics. 2017;18(16):1491–1502.Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clinical pharmacology and therapeutics. 2008;83:234–242.Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clinical pharmacology and therapeutics. 2008;83:234–242.Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews. 2009;41(2):289–295.Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews. 2009;41(2):289–295.Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009; 14(10):536-46.Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009; 14(10):536-46.Komar AA. Silent SNPs: impact on gene function and phenotype. Pharmacogenomics. 2007;8(8):1075–1080.Komar AA. Silent SNPs: impact on gene function and phenotype. Pharmacogenomics. 2007;8(8):1075–1080.

The authors declare that there are no conflicts of interest present.